Beta-Blocker Therapy (i.e., Bisoprolol, Carvedilol, or Sustained-Release Metoprolol Succinate) for Left Ventricular Systolic Dysfunction (LVSD) Prescribed at Discharge

INACTIVE REVIEW: This measure review is older than five years.

Proportion of heart failure patients age18 and older with LVSD for whom beta-blocker therapy (i.e., bisoprolol, carvedilol, or sustained-release metoprolol succinate) is prescribed at discharge. For purposes of this measure, LVSD is defined as chart documentation of a left ventricular ejection fraction (LVEF) less than 40% or a narrative description of left ventricular systolic (LVS) function consistent with moderate or severe systolic dysfunction.

Date Reviewed: November 7, 2015

Measure Info

NQF 2438 NQF Endorsement Removed
Measure Type
Measure Steward
The Joint Commission
Clinical Topic Area
Heart Failure

Care Setting
Data Source
Electronic Health Records
Paper Medical Records

ACP supports this measure because it is evidence-based, aligns with current clinical recommendations, and is low burden to physicians, as the data is automatically captured in the electronic medical record.